NGM-831

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameNGM-831
Drug Alias NameNGM-831
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionImmunomodulatorsLeukocyte immunoglobulin-like receptor subfamily B member 4 inhibitors
TargetsLeukocyte immunoglobulin-like receptor subfamily B member 4
Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsUterine Cervical Neoplasms +[16] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNGM Biopharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesNGM Biopharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic NeoplasmsUterine Cervical Neoplasms +[16] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A